Abstract:Vascular complications, such as impaired vasodilation, are a major problem that obese individuals face. In obesity, epididymal white adipose tissue (eWAT) expands, undergoes phenotypic changes, and begins to secrete a variety of adipokines that can metabolically regulate other organs and tissues including the cardiovascular system. Human studies report high levels of asprosin, a newly discovered adipokine secreted by WAT, in obesity. In this study, we hypothesize that obesity increases asprosin expression in eWAT which correlates to vascular complications.Eight-week-old male C57BL/6 mice were randomized into two experimental groups. The control group (n=7) received a standard chow diet (5% fat, 48.7% carbohydrates [3.2% sucrose]) and the Western Diet (WD) group (n=11) received a WD (40% fat, 43% carbohydrates [34% sucrose]) for 39 weeks. Obesity was confirmed by increased body weight (45.39 ± 1.98 g vs. 29.21 ± 0.79 g controls, p< 0.05) and increased BMI (0.45 ± 0.12 kg/m 2 vs. 0.32 ± 0.01 kg/m 2 controls, p< 0.05). At terminal experiments, eWAT was collected for histological and biochemical analysis. As expected, obese mice exhibited a greater amount of eWAT in comparison to the control group (2.69 ± 0.14 mg/g vs. 0.58 ± 0.06 mg/g controls, p< 0.05). Histological analysis of eWAT stained with H&E revealed that obesity induced a significant increase in adipocyte's size (10543.47 ± 694.06 μm 2 vs.1726.64 ± 152.20 μm 2 controls, p< 0.05) and infiltration of inflammatory cells surrounding adipocytes. Strikingly, greater asprosin expression was detected in eWAT from WD group in comparison to the control group (1.3 fold of increase, p<0.005). To assess whether asprosin has vascular effects, mesenteric arteries from control C57BL/6 mice were acutely incubated with pharmacological concentration of asprosin followed by vascular studies assessed by wire myograph. Our preliminary results show that asprosin impairs endothelium-dependent vasodilation (Emax:72.95% ± 7.38 vs. 93.33% ± 1.33 controls, n=3).The novelty of our results show that asprosin has a negative effect in vascular function. Our findings imply that eWAT may be a tissue contributing to the high levels of asprosin in obese individuals, further suggesting asprosin as a culprit of obesity-associated vascular dysfunction in obese males. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Asprosin aggravates vascular endothelial dysfunction via disturbing mitochondrial dynamics in obesity models.

Asprosin Exacerbates Endothelium Inflammation Induced by Hyperlipidemia Through Activating IKKβ-NF-κBp65 Pathway

Asprosin contributes to pathogenesis of obesity by adipocyte mitophagy induction to inhibit white adipose browning in mice

Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species

Asprosin aggravates atherosclerosis via regulating the phenotype transformation of vascular smooth muscle cells

Increased asprosin in epididymal adipose tissue as a potential contributor to impaired vascular function in obese mice.

Angiogenesis–Browning Interplay Mediated by Asprosin-Knockout Contributes to Weight Loss in Mice with Obesity

Jianpi Qutan Fang induces anti-atherosclerosis and ameliorates endothelial cell injury in high-fat diet ratsan anti-inflammatory and inhibiting Janus kinase/signal transducer and activator of transcription signaling pathway

Asperuloside as a Novel NRF2 Activator to Ameliorate Endothelial Dysfunction in High Fat Diet-Induced Obese Mice

Asprosin promotes vascular inflammation via TLR4-NFκB-mediated NLRP3 inflammasome activation in hypertension

Novel adipokine asprosin modulates browning and adipogenesis in white adipose tissue

Asprosin Induces Vascular Endothelial-to-mesenchymal Transition in Diabetic Lower Extremity Peripheral Artery Disease

The role of Asprosin in patients with dilated cardiomyopathy

Asperuloside activates hepatic NRF2 signaling to stimulate mitochondrial metabolism and restore lipid homeostasis in high fat diet-induced MAFLD

Elevated Circulating Asprosin Impedes Low Intensity Exercise-induced Weight Loss In Obese Individuals: 3893 Board #210 May 30 9:00 AM - 10:30 AM

Asperuloside Improves Obesity and Type 2 Diabetes through Modulation of Gut Microbiota and Metabolic Signaling

Diet and exercise interventions reduce serum asprosin and the corresponding hypothalamic- pituitary-gonad-axis dysfunction in obese men

Asprosin: A Novel Player in Metabolic Diseases

Asprosin: its function as a novel endocrine factor in metabolic-related diseases

Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects

Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway